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Abstract
Aim of the study: This multicentre study aimed to examine the actual risk for drug-drug interactions in a cohort 
of Polish patients, and their impact on antiviral therapy.
Material and methods: Concomitant medications were analyzed in hepatitis C virus (HCV)-infected patients 
treated with still valuable therapy with OBV/PTV/r ± DSV ± RBV. An established online tool (http://www.
hep-druginteractions.org/) was used to assess potential drug interactions. To assess the impact of comedications 
on virologic outcomes, HCV RNA levels were measured at given time points during and after the treatment. The 
results were compared between subgroups depending on the number of drugs used.
Results: Among the 209 patients included in this multicentre study, concomitant medications were taken by 
140 (67.0%) patients. Modification of treatment due to expected interactions was required in 33 (15.8%) 
patients, of whom nine (4.3%) had at least one comedication replaced or discontinued. Sustained virologic 
response rates ranged from 95.1% to 100.0%, and were lowest in patients taking one to five comedications who 
were null-responders to pegylated interferon or cirrhotic.
Conclusions: Although most HCV-infected patients received concomitant medications, only some required treat-
ment modification. OBV/PTV/r ± DSV ± RBV was effective in all subgroups, irrespective of the number of come-
dications taken. Multimorbidity and polypharmacy in patients with chronic hepatitis C should not discourage the 
decision to initiate antiviral therapy, although caution should be exercised for potential drug-drug interactions.
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Introduction
Despite significant advances in antiviral therapies, 
hepatitis C virus (HCV) infection and its consequenc-
es remain a significant health concern worldwide. De-
velopment of all-oral interferon (IFN)-free regimens, 
including genotype specific and pangenotypic regi-
mens, revolutionized treatment of chronic hepatitis C, 
offering both high rates of virologic success and good 
tolerability [1]. Excellent outcomes in most patient 
populations, including those with advanced liver dis-
ease, were noted in clinical trials and subsequently 
replicated in an array of real-world observations [2-4]. 
The combination of three direct-acting antivirals 
(DAAs) with different mechanisms of action (i.e., the 
NS5A inhibitor ombitasvir [OBV], ritonavir-boosted 
NS3/4A protease inhibitor paritaprevir [PTV], and the 
NS5B polymerase inhibitor dasabuvir [DSV], alone 
or with addition of ribavirin [RBV]) is registered for 
treatment of hepatitis C genotype 1 and 4 in the United 
States and Europe. Although the regimen was proven 
effective and safe in HCV-infected patients with or 
without coexisting morbidities, a  number of drug-
drug interactions (DDIs) are expected upon co-ad-
ministration with other therapeutics [5-8]. This is 
particularly important as polypharmacy is frequently 
observed in patients undergoing anti-HCV treatment, 
especially those with liver cirrhosis, a history of liver 
transplantation, or affected by concomitant non-he-
patic disorders.
The high potential for DDIs can be attributed to 
common metabolic pathways and the almost univer-
sal propensity of DAAs to influence cytochrome P450 
(CYP) enzymes and drug transporters, by acting as 
their substrates, inhibitors and/or inductors [9]. The 
effect of DAAs on hepatocyte drug metabolism may 
also result in abnormal exposures to other medications 
and hinder or augment their action. Due to its distinct 
metabolism, RBV probably does not contribute to in-
teractions associated with DAA therapy [10].
Previous studies estimated that two-thirds of pa-
tients with chronic HCV infection take at least one 
medication with the potential for DDIs involving 
CYP3A [11]. Another study showed that interactions 
with regular medication were expected in 66.3% of pa-
tients treated with OBV/PTV/r, with 8.4% of patients 
taking at least one drug whose coadministration with 
DAAs was contraindicated (the addition of DSV did 
not change these numbers) [12]. Furthermore, avail-
able real-world data suggest that regimens containing 
protease inhibitors are associated with higher risk of 
DDIs compared to other DAA therapies [12, 13].
In our recent study (i.e., the AMBER study), we 
demonstrated that OBV/PTV/r ± DSV ± RBV had 
excellent effectiveness and safety in clinical practice, 
despite the high rate of polypharmacy among patients 
[2]. In the present study, we aimed to investigate po-
tential DDIs between OBV/PTV/r ± DSV and other 
therapeutics used by the AMBER study participants, 
and their impact on the treatment outcomes.
Material and methods
Study design and population
This multicentre real-world study was conducted 
according to Good Clinical Practice principles and in 
line with the Declaration of Helsinki. It was approved 
by a local ethics committee of each participating cen-
ter.
HCV genotype 1 or 4-infected patients, male or fe-
male, who were previously treated or treatment-naïve, 
and who enrolled for treatment with OBV/PTV/r 
± DSV ± RBV according to the therapeutic guidelines, 
were evaluated. A  full list of inclusion and exclusion 
criteria can be found in the main study paper [2].
Laboratory and demographic data were gathered 
retrospectively, including comorbidities and current 
medication. Patients were assigned to one of three sub-
groups depending on the number of medications and 
risk of interaction of drugs [14, 15] taken before anti-
viral treatment was started: A – no concomitant med-
ications, B – less than five concomitant medications, 
C – five or more concomitant medications.
Comedications
Prior to the initiation of antiviral treatment, infor-
mation regarding concomitant medications was care-
fully analyzed. To assess for possible DDIs, a general-
ly accessible online tool was used (available at http://
www.hep-druginteractions.org/) [16]. Based on the 
search results, comedications were assigned to the 
following four categories (as defined by the tool’s au-
thors): do not coadminister, potential interaction, no 
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interaction expected, or no clear data. Drugs identified 
as contraindicated were discontinued or replaced prior 
to commencement of OBV/PTV/r ± DSV ± RBV ther-
apy. When necessary, dosing of concomitant medica-
tions was modified according to recommendations.
Virologic and safety assessment
HCV RNA levels were obtained with quantitative 
polymerase chain reaction (PCR) assays at baseline, 
week 4, end of treatment (EOT), and 12 weeks after 
EOT (FU12). The HCV RNA detection threshold var-
ied across study centers but in all cases was lower than 
18 IU/ml. The efficacy endpoint was achievement of 
a sustained virologic response (SVR), i.e., undetectable 
HCV RNA at FU12. Adverse events were collected and 
reported by the investigators from baseline until 30 days 
after completion of antiviral treatment.
Statistical analysis
Data are presented as mean ± standard deviation 
(SD) unless indicated otherwise. HCV RNA levels were 
logarithmically transformed. A p-value of 0.05 was con-
sidered significant. Statistical analyses were performed 
with STATISTICA 12.0 (StatSoft, Tulsa, OK, USA).
Results
Among the 209 patients included in the study, 
use of concomitant medications was reported in 140 
(67.0%), with 33 (15.8%) taking five or more drugs. 
The proportion of patients with liver cirrhosis (F4 ac-
cording to METAVIR) was greatest among patients re-
ceiving one to five concomitant medications (67/107, 
62.6%). Meanwhile, the highest mean Child-Pugh and 
Model for End-Stage Liver Disease (MELD) scores 
were observed in patients taking five or more concom-
itant medications (5.6 and 8.7 points, respectively). In 
addition, the proportion of null-responders to previ-
ous antiviral therapy was also highest in those taking 
> 5 concomitant medications (17/33, 51.5%). Demo-
graphic and laboratory data are presented in Table 1.
Figure 1 shows the number of concomitant medi-
cations taken by the patients. The most common drugs 
taken by the patients were pantoprazole (17 patients, 
8.1%), furosemide (15 patients, 7.2%), spironolactone 
(14 patients, 6.7%), and ursodeoxycholic acid (14 pa-
tients, 6.7%). Concomitant medications and their po-
tential for interactions with OBV/PTV/r ± DSV are 
listed in Table 2. RBV was not included in the analysis.
The most common comorbidities were arterial hy-
pertension (57/209, 27.3%), obesity (38/209, 18.2%), 
and diabetes (33/209, 15.8%). A detailed list of coexist-
ing disorders is shown in Table 3.
Modification of current treatment with regard to 
antiviral therapy was required in 33 (15.8%) patients; 
in most cases (31 patients, 14.8%), modification oc-
curred prior to the initiation of OBV/PTV/r ± DSV 
± RBV. The remaining two patients had their con-
comitant medications modified on-treatment due to 
clinically significant adverse events (in both cases the 
patients had arterial hypertension and the medications 
were discontinued or reduced because of hypotension). 
Of the patients who required treatment modification, 
nine (4.3%) had at least one concomitant medication 
changed or discontinued, and in 26 (12.4%) the dose 
of one or more drug was reduced (Fig. 2). Most often, 
the reduction of dose pertained to immunosuppres-
sive medications taken by orthotopic liver transplant 
(OLTx) recipients.
OBV/PTV/r ± DSV ± RBV was effective in all sub-
groups with SVR rates ranging from 95.1% to 100.0% 
depending on treatment history and degree of liver fi-
brosis. Poorer results were observed in patients taking 
one to five concomitant medications with a history of 
non-response to previous pegylated (PEG)-IFN-based 
therapy (97.4%) and those with liver cirrhosis (97.0%).
Virologic outcome across subgroups is shown in 
Figure 3. HCV RNA dynamics was similar indepen-
dent of the number of drugs taken, although two 
patients (both taking one to five concomitant medi-
cations) failed to eliminate the virus. Changes in the 
HCV viral load in the three subgroups (A, B, and C) 
are presented in Figure 4.
Discussion
Patients with chronic hepatitis C, especially those 
with liver cirrhosis and a  history of hepatic decom-
pensation, often require long-term use of medication. 
Moreover, a considerable proportion of these patients 
present with other problems in addition to liver dis-
ease and its consequences. For example, it has long 
been observed that patients with chronic HCV in-
fection have higher prevalence of glucose intolerance 
and are at greater risk of developing type 2 diabetes 
[17, 18]. A  relationship between chronic hepatitis C 
and cardiovascular diseases has also been investigat-
ed [19]. Likewise, comorbidities were common in our 
study population, with almost 50% of the patients re-
porting at least one endocrine or metabolic disorder, 
and over 30% treated for one or more cardiovascular 
disease (usually hypertension). In addition, 67% of pa-
tients required regular medication aside from antiviral 
treatment.
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The rate of advanced liver fibrosis (F3 or F4 ac-
cording to METAVIR) was also high (72.2%) among 
our study cohort. Similar findings were shown in an-
other real-world cohort receiving DAAs or pegylated 
interferon (PEG-IFN)-containing regimens [12] in 
which 80% of patients took at least one concomitant 
medication, and the rate of advanced liver disease was 
comparable to that in our observation (78%). This 
reflects the general characteristics of chronic hepati-
tis C patients currently enrolled for treatment. Given 
the natural history of HCV infection and considerable 
rate of non-response to PEG-IFN-based therapies, the 
Table 1. Clinical and laboratory characteristics of the study group (N = 209)







Age, years (±SD) 48.7 (13.1) 53.2 (12.0) 58.0 (8.7)
Gender
Male, n (%) 33 (47.8) 39 (36.4) 21 (63.4)
BMI, kg/m2 (±SD) 25.2 (3.9) 26.9 (3.9) 27.1 (3.7)
Treatment history, n (%)
Naïve 18 (26.1) 23 (21.5) 3 (9.1)
Partial responder 8 (11.6) 8 (7.5) 1 (3.0)
Relapser 11 (15.9) 20 (18.7) 6 (18.2)
Null-responder 26 (37.7) 41 (38.1) 17 (51.5)
Discontinued 3 (4.3) 8 (7.5) 1 (3.0)
Unknown 3 (4.3) 7 (6.5) 5 (15.2)
Fibrosis stage, n (%)
F0 2 (2.9) 0 (0.0) 2 (6.1)
F1 8 (11.6) 8 (7.5) 5 (15.2)
F2 11 (15.9) 10 (9.3) 8 (24.2)
F3 8 (11.6) 20 (18.7) 4 (12.1)
F4 40 (58.0) 67 (62.6) 12 (36.4)
HCV genotype, n (%)
1a 9 (13.0) 3 (2.8) 1 (3.0)
1b 52 (75.4) 92 (86.0) 32 (97.0)
1 (subgenotyping not available) 3 (4.3) 4 (3.7) 0 (0.0)
4 4 (5.8) 5 (4.7) 0 (0.0)
HCV RNA level, × 106 IU/ml (SD) 1.3 (2.0) 1.3 (1.8) 2.2 (2.7)
Bilirubin, mg/dl (SD) 2.6 (12.1) 4.0 (16.57) 1.2 (0.84)
ALT, IU/ml (SD) 106.5 (91.3) 105.6 (75.8) 79.6 (44.9)
INR (SD) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2)
Hemoglobin, g/dl (SD) 14.5 (1.6) 14.7 (1.5) 13.7 (1.8)
PLT, × 103 cells/µl (SD) 154.8 (83.3) 123.4 (62.2) 148.8 (72.0)
Albumin, g/dl (SD) 5.5 (11.9) 4.9 (9.5) 4.0 (0.7)
Alpha fetoprotein, µg/l (SD) 14.5 (26.7) 15.8 (28.3) 39.9 (119.8)
Creatinine, mg/dl (SD) 0.8 (0.2) 0.8 (0.2) 1.0 (0.4)
Child-Pugh score, points (SD) 5.2 (0.6) 5.4 (0.8) 5.6 (1.1)
MELD score, points (SD) 8.0 (2.6) 8.3 (2.7) 8.7 (3.2)
ALT – alanine transaminase, BMI – body mass index, HCV RNA – HCV ribonucleic acid, INR – international normalized ratio, MELD – Model for End-Stage Liver Disease, PLT – platelet 
count, SD – standard deviation
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group of older, cirrhotic patients, often with coexisting 
non-hepatic pathologies, is sizeable. For this popula-
tion, DAAs are usually the only viable option.
Despite carrying an increased risk of adverse drug 
reactions and DDIs, polypharmacy is common and of-
ten unavoidable. Use of additional medication in pa-
tients receiving DAAs not only magnifies the probabil-
ity of adverse events, but also may negatively influence 
virologic outcomes. Depending on the site and mecha-
nism of interaction, DDIs can result in abnormal levels 
of regular patient medications or of the antiviral drugs. 
Insufficient concentrations of DAAs heighten the risk 
of virologic failure and allow for the selection of resis-
tance-associated variants [20]. Similarly, diminished or 
no effect of other medications can be expected if their 
levels fall below the therapeutic threshold. Meanwhile, 
too high drug concentrations are associated with an 
increased rate of adverse reactions and/or toxicity.
Novel anti-HCV medications are primarily metab-
olized in the liver via CYP enzymes and drug trans-
porters [8, 21]. Therefore, interactions with substances 
that share these metabolic pathways (or those that act 
as enzyme inhibitors or inducers) are expected. In our 
study, the most common comedications were panto-
prazole (proton-pump inhibitor, PPI), furosemide 
(sulfonamide diuretic), spironolactone (aldosterone 
antagonist), and ursodeoxycholic acid. Our findings 
are generally in line with those presented by other re-
searchers, although few real-world data regarding co-
medications in patients receiving DAAs were available 
at the time of writing [12, 13].
Common use of diuretic agents is not surprising giv-
en the characteristics of the studied population, and the 
considerable proportion of patients with liver cirrhosis 
and its complications. Proton pump inhibitors (PPIs) 
are generally overprescribed and overutilized in the out-
patient setting, which has been subject to epidemiologic 
as well as pharmacoeconomic analyses [22]. It is likely 
that the same takes place in individuals with chronic 
hepatitis C, although the appropriateness of medication 
use has not been investigated in our study. PPIs have 
also been associated with the capacity to alter bioavail-
Number of concomitant medications





















n = 21 n = 20
n = 11 n = 9
n = 5 n = 3 n = 0 n = 1
n = 4
Table 2. Most common concomitant medications including expected drug-
drug interactions with antiviral therapy*




Pantoprazole 17 (8.1) Potential weak interaction
Furosemide 15 (7.2) Potential interaction
Spironolactone 14 (6.7) No interaction expected
Ursodeoxycholic acid 14 (6.7) No interaction expected
Mycophenolate 11 (5.3) Potential interaction
Tacrolimus 11 (5.3) Potential interaction
Insulin 10 (4.8) No interaction expected
Levothyroxine 10 (4.8) Potential interaction
Acetylsalicylic acid (aspirin) 9 (4.3) No interaction expected
Bisoprolol 8 (3.8) Potential interaction
Prednisone 8 (3.8) Potential interaction
Propranolol 8 (3.8) No interaction expected
Prednisolone 7 (3.3) No data
Alfacalcidol 6 (2.9) No data
Amlodipine 6 (2.9) Potential interaction
Omeprazole 6 (2.9) Potential weak interaction
Torasemide 6 (2.9) No interaction expected
Calcium 6 (2.9) No data
Vitamin K (phytonadione) 6 (2.9) No data
Carvedilol 5 (2.4) Potential interaction
Magnesium 5 (2.4) Potential interaction
Metformin 5 (2.4) No interaction expected
Ornithine aspartate 4 (1.9) No data
Azathioprine 4 (1.9) No interaction expected
Indapamide 4 (1.9) Potential interaction
Metoprolol 4 (1.9) No interaction expected
Ramipril 4 (1.9) No interaction expected
Potassium 4 (1.9) No interaction expected
Ranitidine 4 (1.9) No interaction expected
Valsartan 4 (1.9) Potential interaction
Cyclosporine 3 (1.4) Potential interaction
Nebivolol 3 (1.4) No interaction expected
Losartan 3 (1.4) No interaction expected
Hydrochlorothiazide 3 (1.4) No interaction expected
Gliclazide 3 (1.4) Potential interaction
Betahistine 3 (1.4) No data
Allopurinol 3 (1.4) No interaction expected
*The analysis did not include ribavirin. **Based on data from the online drug interaction 
tool (http://www.hep-druginteractions.org/)
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ability of other medications by inducing changes in gas-
tric acidity. So far, this possible negative effect on DAA 
therapy has not been reflected in clinical practice, and 
an analysis of 2,053 patients treated with OBV/PTV/r 
± DSV showed that high rates of PPI coadministration 
(15%) did not affect virologic outcomes [23].
Although the use of concomitant medications was 
frequent in our study (67.0%), modification of treat-
ment to avoid well-known negative interactions (i.e., 
discontinuation or dose reduction prior to initiation 
of DAA therapy) was only necessary in 15.8% of pa-
tients, and pertained predominantly to tacrolimus, 
cyclosporine, amlodipine, and furosemide. However, 
a  predominant part of this group (and 10.0% of the 
entire study population) comprised OLTx recipients 
on regular immunosuppressive therapy, which im-
plies that even lower numbers should be expected in 
a population without a history of OLTx. Furthermore, 
the proportion of patients who required modifica-
tion of regular therapy after the initiation of antiviral 
treatment did not exceed 1% (i.e., two cases). In both 
of these cases, DDIs led to excessive serum levels of 
hypertensive medication presenting as symptomatic 
hypotension. This adverse reaction was successfully 
handled with hypertensive medication dose reduction, 
and both patients completed antiviral therapy.
In addition to safety concerns, polypharmacy in 
individuals receiving DAAs may increase the risk of 
virologic failure in a manner already described above. 
However, this was not observed in our study. After dis-
continuation of drugs whose coadministration with 
OBV/PTV/r ± DSV was contraindicated, the number 
of comedications had no effect on HCV RNA dynam-
ics during treatment, or on final virologic outcome. At 
FU12, HCV RNA was undetectable in 99% of patients, 
and only two failed to achieve an SVR (in both cases, 
patients were taking between one and five drugs be-
sides antiviral therapy and were prior null-responders 
with advanced liver disease). SVR rates were lower in 
subpopulations that are historically difficult to treat 
(i.e., non- and null-responders to previous antiviral 
therapies, patients with liver cirrhosis) irrespective of 
the number of concomitant medications.
Our study is subject to limitations. As data regard-
ing concomitant medications came from the patients, 
a  risk of underreporting exists, particularly where 
non-prescription preparations are concerned. In addi-
tion, certain foods and dietary or herbal supplements 
are known to have inhibitory or inducing effects on 
enzymes or transporters involved in the metabolism 
of drugs, including DAAs. Given the absence of inter-
action studies with this group of medications, coad-
ministration should probably be avoided. It is the role 





Thyroid disorders 26 (12.4)
Other 2 (1.0)
Cardiovascular 70 (33.5)
Arterial hypertension 57 (27.3)

































AIH – autoimmune hepatitis, CKD – chronic kidney disease, COPD – chronic obstructive 
pulmonary disease, HCC – hepatocellular carcinoma
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Fig. 2. Proportion of patients requiring modification of current treatment prior 


















n = 33 n = 26
n = 9
DSV – dasabuvir, OBV – ombitasvir, PTV – paritaprevir, r – ritonavir, RBV – ribavirin
Any modification Change 
or discontinuation
Dose reduction
Fig. 3. Sustained virologic response rates across the three subgroups. A) No comedications. B) 1-5 comedications. C) ≥ 5 comedications
DSV – dasabuvir, OBV – ombitasvir, OLT – orthotopic liver transplant, PEG-IFN – pegylated interferon, PI – protease inhibitor, PTV – paritaprevir, r – ritonavir, RBV – ribavirin,  
SVR – sustained virologic response
No comedications (n = 69)
All, n = 69
All non-responders, n = 48
Null-responders to PEG-IFN + RBV, n = 26
Cirrhotic, irrespective of treatment history, n = 40
Child-Pugh, n = 2








1-5 comedications (n = 107)
All, n = 107
All non-responders, n = 77
Null-responders to PEG-IFN + RBV, n = 41
Cirrhotic, irrespective of treatment history, n = 67
Child-Pugh, n = 9









≥ 5 comedications (n = 33)
All, n = 107
All non-responders, n = 25
Null-responders to PEG-IFN + RBV, n = 17
Cirrhotic, irrespective of treatment history, n = 12
Child-Pugh, n = 3









of the physician to inform patients of potential risks 
arising from simultaneous use of antivirals and oth-
er therapeutics, especially since a growing number of 
them are now available over the counter.
Apart from pharmaceutical and pharmacological 
data presented as scientific papers or specified in the 
summaries of product characteristics, convenient on-
line tools are now available to facilitate management 
of potential DDIs [16, 24-26]. It should, however, be 
noted that most information has come from in vitro 
observations and studies conducted in healthy vol-
unteers, and more research is needed to provide real- 
world data. Furthermore, data for some therapeutics 
are unclear or missing.
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No comedications (n = 69)
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Fig. 4. HCV RNA dynamics in the three subgroups during treatment and 
follow-up. A) No comedications. *data available for 18/69 patients; 
**data available for 24/69 patients; ***data available for 59/69 patients. 
B) 1-5 comedications. *data available for 30/107 patients; **data 
available for 44/107 patients; ***data available for 96/107 patients. 
C) ≥ 5 comedications. *data available for 11/33 patients; **data available 
for 16/33 patients; ***data available for 31/33 patients
EOT – end of treatment, FU12 – follow-up at 12 weeks after EOT, TD, HCV RNA 
detectable but below the limit of quantifications; TND, HCV RNA undetectable
≥ 5 comedications (n = 33)
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Introduction of DAAs has undoubtedly marked 
a  milestone in the history of hepatitis C treatment. 
OBV/PTV/r ± DSV is effective and well tolerated in 
HCV-infected patients, including those with a  high 
degree of fibrosis, history of non-response to previous 
treatments, or in liver transplant recipients. Although 
DDIs can be expected in patients receiving concomi-
tant medications, in the setting of real-world clinical 
practice they are manageable, and do not affect viro-
logic outcome. Careful collection and analysis of data 
regarding current medication are necessary to mini-
mize the risk of adverse events and/or therapeutic fail-
ure. In addition, on-treatment monitoring is crucial to 
ensure maximal safety. Last but not least, improving 
the interaction profile, along with shortening the du-
ration of treatment and facilitating adherence, remains 
a challenge.
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